zinc finger protein 300 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored ZNF300P1 profile across patient tissues and cancer cell-line models. ZNF300P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF300P1 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, ZNF300P1 RNA expression shows 16,107 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where ZNF300P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF300P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF300P1 survival associations across molecular data types. ZNF300P1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF300P1 RNA expression–survival associations across cancer types. High ZNF300P1 expression shows favorable associations in KIRP, THYM, UCS, LAML, KIRC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF300P1 RNA expression.
This table summarizes ZNF300P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF300P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF300P1 shows lower tumor expression in KIRC, KICH, LUSC, LUAD, COAD and BLCA. The KIRC box plot shows higher ZNF300P1 RNA expression in normal versus tumor tissue (log2 FC = −1.379, t-test p < 0.001).
This table shows molecular features associated with ZNF300P1 in patient tissues and cancer cell lines. In patient samples, ZNF300P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
